Drug Sentece Context
Table 1. Analysis of context sentence of denosumab gene in 3 abstracts.
|32396134||Patients established on denosumab and teriparatide should continue planned therapy.|
|32904892||Targeting the RANK-RANKL system should be a priority, and denosumab could represent a safe and effective choice.|
|33080571||Denosumab, zoledronate and calcium were negatively associated with COVID-19 incidence.|
|33249579||The anti-receptor activator of nuclear factor-κΒ ligand (RANKL)-targeted agent denosumab has shown its non-inferiority compared to bisphosphonates in preventing skeletal-related events among newly diagnosed patients with myeloma bone disease. […] Denosumab may confer a survival benefit in patients eligible for autologous transplantation. […] Denosumab may present a safer profile for patients with renal impairment. […] Discontinuation of bone-directed therapies can be considered for patients with deep responses and after an adequate time period on treatment; however, a rebound effect may become evident especially in the case of denosumab. […] Three-monthly infusions of zoledronic acid or at-home denosumab administration should be considered during the coronavirus disease 2019 (COVID-19) pandemic.|
|33415510||Treatment with intravenous bisphosphonates and denosumab was delayed according to 35 (45.4%) and 6 (6.3%) of the respondents, respectively.|